CAJ | 학술논문

目的探讨雌激素对绝经后骨质疏松症(postmenopausal osteoporosis，PMO)的防治作用。方法本研究用QCT法测定腰椎L2～L4骨密度，并行骨代谢一般生化指标测试，观察48例绝经后妇女的骨量变化，用天然结合雌激素倍美力防治骨质疏松的作用。结果48例研究对象治疗前均有骨密度下降，其中32人患有骨质疏松，占66.67％；未用倍美力治疗者23例(对照组)骨密度继续下降，自身对照有显著差异(P＜0.01)；倍美力0.625mg/d治疗者25例(治疗组)，一年后测试骨密度无明显变化，说明倍美力能减缓骨密度下降。治疗组服用倍美力后尿钙/肌酐、尿羟脯氨酸/肌肝比值均有下降(P＜0.05)，对照组则不明显，两组治疗后尿羟脯氨酸/肌肝比值有明显差异(P＜0.05)。结论提示倍美力能有效地减缓骨吸收速度，减少骨质丢失，从而防止骨质疏松的发生。
목적탐토자격소대절경후골질소송증(postmenopausal osteoporosis，PMO)적방치작용。방법본연구용QCT법측정요추L2～L4골밀도，병행골대사일반생화지표측시，관찰48례절경후부녀적골량변화，용천연결합자격소배미력방치골질소송적작용。결과48례연구대상치료전균유골밀도하강，기중32인환유골질소송，점66.67％；미용배미력치료자23례(대조조)골밀도계속하강，자신대조유현저차이(P＜0.01)；배미력0.625mg/d치료자25례(치료조)，일년후측시골밀도무명현변화，설명배미력능감완골밀도하강。치료조복용배미력후뇨개/기항、뇨간포안산/기간비치균유하강(P＜0.05)，대조조칙불명현，량조치료후뇨간포안산/기간비치유명현차이(P＜0.05)。결론제시배미력능유효지감완골흡수속도，감소골질주실，종이방지골질소송적발생。
Objective To evaluate the preventive action of estrogen on postmenopausal osteo- porosis (PMO). Methods We performed bone density determination of the lumbar vertebrae L2～L4 by QCT and general biochemistry index assay of bone metabolism in order to observe the bony weight change of 48 postmenopausal women and the preventive action of natural conjugated estrogen. Results Thirty-two of 48 postmenopausal women with a fall of bone density suffered osteoporosis (66.67 ％ ): in the test group (25 cases) 0. 625mg of Premarin had been taken per day for one year and bone density had no apparent change; and in the contrast group without Premarin administration, bone density continued to lose, their self - contrast had significant difference ( P ＜ 0.01 ). It is thus certified that Premarin can effectively delay the falling speed of bony density. The ratios of urinary - calcium/cre- atinine and urinary hydroxproline/creatinine in test group have failed down ( P ＜ 0.05)pre and post medication, but it was not noticeable in the contrast group. The ratio of urinary hydroxproline/ creatinine after treatment had significant difference between two groups (P ＜ 0. 05 ). Conclusion Premarin can effectively slow down bone absorption and reduce bone loss so as to prevent osteoporosis.